The incidence of CNS metastases is higher still among patients with non-small cell lung cancer (NSCLC) and driver oncogenes, especially EGFR mutations and ALK rearrangements, in whom up to 60% will develop brain metastases [3,4,5]. Here, ALK is linked to non-small cell lung carcinoma.